CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Asfotase alfadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02797821
NCT02797821Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Multicenter, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia

Alexion Pharmaceuticals, Inc.·interventional·Posted Jun 14, 2016·Updated Sep 17, 2019

In Brief

A Phase 2 clinical trial evaluating Asfotase alfa for Hypophosphatasia. Completed, enrolled 27 participants across 4 sites in 2 countries.

Detailed Summary

The purpose of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of asfotase alfa in adult participants with pediatric-onset HPP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypophosphatasia
CountriesGermany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 14, 2016
Enrollment StartJun 6, 2016
Primary CompletionJun 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.0 years ago

Interventions

Asfotase alfadrug